As reported on News Medical, researchers are highlighting a new class of therapies that could improve outcomes for people living with primary biliary cholangitis (PBC), a chronic autoimmune liver disease that can eventually lead to cirrhosis and liver failure.
PBC develops when the body’s immune system mistakenly attacks the small bile ducts within the liver. As these ducts become damaged, bile accumulates in the liver, triggering inflammation and progressive tissue injury. Although ursodeoxycholic acid remains the standard first-line treatment, a substantial proportion of patients either do not achieve an adequate response or are unable to tolerate the therapy, creating a need for additional therapeutic options.
A recent review published in Trends in Molecular Medicine examines the growing role of peroxisome proliferator-activated receptors (PPARs) as promising targets for PBC treatment. The research was led by Professor Manuel Vázquez-Carrera of the University of Barcelona, along with colleagues from the University of Barcelona Institute of Biomedicine, Sant Joan de Déu Research Institute, and CIBERDEM.
PPARs Show Potential to Address Key Disease Mechanisms
The review summarizes current evidence on how PPAR activation may influence several biological pathways involved in PBC progression. These receptors help regulate important aspects of liver function, metabolism, and inflammation.
According to the researchers, activating PPARs may help reduce inflammatory activity, improve bile acid regulation, and limit the development of liver fibrosis. Fibrosis, characterized by the buildup of scar tissue in the liver, is a major contributor to declining liver function and disease progression.
The authors also evaluated data on PPAR agonists, a category of drugs designed to activate these receptors. Among the therapies discussed are elafibranor and seladelpar, two recently approved treatments that have broadened the therapeutic landscape for patients who require options beyond first-line care.
Links Between PBC and Metabolic Disease
Beyond their relevance to liver disease, PPARs play a significant role in pathways associated with type 2 diabetes. These receptors are involved in regulating lipid metabolism, insulin responsiveness, and inflammatory signaling, all of which can become dysregulated in both metabolic and hepatic disorders.
Researchers suggest that a better understanding of these shared mechanisms could support the development of therapies capable of addressing overlapping biological processes across multiple diseases. Such insights may also contribute to a more comprehensive view of how metabolic dysfunction and liver disease interact.
Growing Role in Second-Line Treatment
Based on currently available clinical evidence, PPAR agonists are emerging as an important treatment strategy for patients who do not respond sufficiently to first-line therapy. Their ability to target inflammation, bile acid imbalance, and fibrosis makes them particularly attractive candidates for disease management.
However, the investigators caution that additional long-term studies are needed. While existing findings are encouraging, further research with extended follow-up will be essential to determine whether these therapies can meaningfully alter disease progression and deliver sustained clinical benefits over time.
